Figure 7.
T-cell profiling of splenocytes after CpG deoxynucleotide/PTT therapy. (A-I) Populations of CD4+ T cells (A), Th1 T cells (CD4+ IFN-γ) (B), Th2 T cells (CD4+ IL-4) (C), Th17 T cells (CD4+ IL-17) (D), Tregs (CD4+CD25+FOXP3+) (E), CD8+ T cells in total T cells (F), IFN-γ–expressing CD8+ T cells (G), granzyme-expressing CD8+ T cells (H), and dual-expressing CD8+ T cells in total T cells (CD45+CD3+) (I). *P < .05, **P < .01 (2-tailed paired t test). ns, not significant.

T-cell profiling of splenocytes after CpG deoxynucleotide/PTT therapy. (A-I) Populations of CD4+ T cells (A), Th1 T cells (CD4+ IFN-γ) (B), Th2 T cells (CD4+ IL-4) (C), Th17 T cells (CD4+ IL-17) (D), Tregs (CD4+CD25+FOXP3+) (E), CD8+ T cells in total T cells (F), IFN-γ–expressing CD8+ T cells (G), granzyme-expressing CD8+ T cells (H), and dual-expressing CD8+ T cells in total T cells (CD45+CD3+) (I). *P < .05, **P < .01 (2-tailed paired t test). ns, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal